Streptococcal pyrogenic exotoxin B (SpeB) (SpeB)

Streptococcal pyrogenic exotoxin B (SpeB), also known as streptopain, is a potent extracellular cysteine protease secreted by Streptococcus pyogenes (Group A Streptococcus). It is recognized as a primary virulence factor because it cleaves a broad spectrum of host proteins, including extracellular matrix components like laminin and fibronectin, immunoglobulins, and complement factors such as C3b. SpeB is secreted as a 40 kDa inactive zymogen that undergoes autocatalytic processing into a 28 kDa mature protease, a process tightly regulated by environmental cues like pH and nutrient availability. Its proteolytic activity facilitates bacterial spread through tissues, degrades host immune mediators to evade detection, and can even trigger host cell pyroptosis by cleaving gasdermin A. In the context of disease, SpeB is heavily implicated in the pathogenesis of severe invasive infections such as necrotizing fasciitis and streptococcal toxic shock syndrome (STSS). It also plays a role in post-infectious sequelae, including rheumatic heart disease, by modulating the inflammatory response. While there are currently no FDA-approved drugs that specifically target SpeB, it is a significant focus for experimental anti-virulence therapies. Potential therapeutic strategies include the use of small-molecule cysteine protease inhibitors like E-64, natural compounds like allicin, and neutralization using intravenous immunoglobulins (IVIG) or novel multi-antigen vaccines currently in clinical development.

Other names

StreptopainStreptococcal cysteine proteinaseExotoxin BStreptococcal cysteine proteaseSpeB proteinaseErythrogenic toxin B

Cysteine protease inhibition or neutralization of toxin activity